about
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumorsSelective delivery of therapeutic agents for the diagnosis and treatment of cancer.Towards a ligand targeted enzyme prodrug therapy: single round panning of a beta-lactamase scaffold library on human cancer cells.Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapyCancer cell-specific internalizing ligands from phage displayed beta-lactamase-peptide fusion libraries.Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancerAdeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth.FOXA1 as a therapeutic target for breast cancer.The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder.Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells.Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptorA review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.The molecular genetics of breast cancer and targeted therapyProgesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.Rethinking the metastatic cascade as a therapeutic target.Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneityPegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.New oral targeted therapies for metastatic breast cancer disrupt the traditional patients' management-A healthcare providers' view.Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas.
P2860
Q28292264-5E6709D1-8E0D-47EA-98E9-8B132147EFD9Q33230098-EAC3D787-AE23-49EA-9911-82BBBA5E5033Q33272567-85DF60FA-9DAB-4CEB-A30E-4FDF2A631C4EQ33502835-5A2457CC-0988-4501-91F9-3538B13767C4Q33539508-1E0F7190-1D31-489D-815F-FC019CF8A26AQ33875800-66090FAA-2796-49C8-BA87-05C432CB10EDQ33989913-FED57678-FC4E-4D1A-8EE2-039B6DA40FA2Q34610510-5237A457-CAF0-4981-947D-BB6E23711E56Q34736121-655FBFD3-593D-4676-8BC8-E836EDC4ABE7Q35428525-CCC23F23-2313-4C66-B724-8FBD29FFED7AQ35910960-C356DD08-61C3-40D5-BC64-E3E2A7CBFE6BQ36642955-E318559F-2E67-4846-AD74-26A10794AB3CQ37290512-BA40C9C9-F033-484C-88FF-0CFC55BFACD0Q37725048-FEF9696B-D285-418D-BE4C-1D5D1748E7AAQ37866635-808070E7-AC2A-4E63-A9A3-0FC2360CEBB4Q40219858-6503C3B8-1281-403D-9862-ABDA01A5FB1DQ40437197-08285111-AA67-4D05-A6A1-6D9CE22F0595Q46882549-317178C2-3725-466A-A3F6-3931188DA020Q48115704-8ADA2FCC-858B-44A6-8F58-1DDD3358E0E3Q48376998-542B3F18-32E9-4061-BAF2-C563DB913A7D
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Targeted therapy: wave of the future.
@ast
Targeted therapy: wave of the future.
@en
type
label
Targeted therapy: wave of the future.
@ast
Targeted therapy: wave of the future.
@en
prefLabel
Targeted therapy: wave of the future.
@ast
Targeted therapy: wave of the future.
@en
P2093
P356
P1476
Targeted therapy: wave of the future
@en
P2093
Alex Bajamonde
Mark D Pegram
Pamela Klein
P304
P356
10.1200/JCO.2005.11.029
P407
P577
2005-03-01T00:00:00Z